Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinosarcoma × pazopanib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 31 Sarcoma 27 Neoplasm Metastasis 15 Ovarian Neoplasms 9 Breast Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Neoplasms 6 Lung Neoplasms 5 Kidney Neoplasms 5 Thyroid Neoplasms 4 Recurrence 4 Melanoma 4 Liposarcoma 4 Leiomyosarcoma 4 Hemangiosarcoma 4 Urinary Bladder Neoplasms 3 Solid Tumors 3 Pancreatic Neoplasms 3 Neurofibrosarcoma 3 Glioblastoma 3 Gastrointestinal Stromal Tumors 3 Chondrosarcoma, Extraskeletal Myxoid 3 Advanced Cancers 3 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solitary Fibrous Tumors 2 Small Cell Lung Carcinoma 2 Sarcoma, Alveolar Soft Part 2 Rhabdomyosarcoma 2

Interventions

Specimen Handling 3 Paclitaxel 3 Nivolumab 3 olaparib 2 X-Rays 2 Carboplatin 2 Biopsy 2 sargramostim 1 pembrolizumab 1 pazopanib 1 pamiparib 1 durvalumab 1 ceralasertib 1 cediranib 1 atezolizumab 1 apatinib 1 Trabectedin 1 Tissue Banks 1 TIC10 compound 1 Minimally Invasive Surgical Procedures 1 Magnetic Resonance Spectroscopy 1 LY-2157299 1 Indocyanine Green 1 Immunoglobulin G 1 Gemcitabine 1 Cyclophosphamide 1 Colony-Stimulating Factors 1 Cisplatin 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02203760 2024-11-15

PazoDoble

North Eastern German Society of Gynaecological Oncology

Phase 2 Active not recruiting

Carcinosarcoma, Leiomyosarcoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡